Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease

Key Inclusion Criteria: * Adult male or females with prior diagnosis of Diabetic Kidney Disease * Type 2 diabetes mellitus diagnosis for at least 6 months * eGFR (MDRD) at screening ≥ 15 mL/min/1.73m\^2 to \< 60 mL/min/1.73m\^2 * Urine albumin to creatinine ratio (UACR) as follows: * Stage/Stratum 3a: eGFR range 45 to \< 60 mL/min; UACR ≥ 600 mg/g * Stage/Stratum 3b: eGFR range 30 to \< 45 mL/min; UACR ≥ 300 mg/g * Stage/Stratum 4: eGFR range 15 to \< 30 mL/min; UACR ≥ 150 mg/g * Receiving angiotensin-converting-enzyme inhibitor (ACEi) or angiotensin receptor blockers (ARB) at a minimum dose deemed appropriate for the individual by the investigator and be at a stable dose for the last three months * Individuals not on ACEi/ARB may be screened if there is documented intolerance to ACE inhibitor and/or ARB Key Exclusion Criteria: * Type 1 diabetes mellitus * HbA1c \> 9.5% * Non-diabetic kidney disease * UACR \> 5000 mg/g on any measurement during screening * End stage renal disease (ESRD; receiving peritoneal dialysis, hemodialysis, or status post renal transplantation) or anticipated to occur within the treatment period * Unstable cardiovascular disease * Pregnant or lactating females Note: Other protocol defined Inclusion/Exclusion criteria may apply.